Serinus Biosciences

Serinus Biosciences is dedicated to addressing a critical challenge in cancer treatment: developing effective combination therapies to combat treatment resistance. The company employs advanced technology to create an AI platform that offers complete explainability, enriched with extensive systems biology data spanning decades. This unique AI engine is specifically designed for biological inference, enabling it to decipher how cancer cells develop resistance to treatments. Consequently, the platform identifies molecules capable of blocking these resistance pathways. Serinus Biosciences aims to design combination therapies that are not only safer and more effective but also can be rapidly delivered to patients. Founded by MIT PhDs and advised by leading academics from institutions like the Broad Institute, Dana-Farber, and UCSD, Serinus is backed by Y Combinator and other prominent investors, striving to revolutionize the field of precision medicine.